Du er på: newsweb.no
newsweb.no
Utsteder
Utst.ID
Instrument
Kategori
Fra dato
Til dato
Velg marked
Vis kun aktive utstedere Info...
  Nullstill...
MeldingsID: 425230
Dato/tid 21.04.2017 08:01
Utsteder PCI Biotech Holding ASA
UtstederID PCIB
Instrument
Marked OAX
Kategori ANNEN INFORMASJONSPLIKTIG REGULATORISK INFORMASJON
Informasjonspliktig   Informasjonspliktige opplysninger   Lagringspliktig melding
Vedlegg
Tittel PCI Biotech: Presentation of fimaChem Phase I data in bile duct cancer at The International Liver Congress 2017
Tekst


Oslo,  Norway, April  21, 2017 PCI Biotech  (OSE:PCIB), a clinical-stage company
developing innovative therapeutics that address significant unmet medical needs,
today announced  that a poster  of the fimaChem  technology will be presented at
the  International  Liver  Congress  2017 -  the  annual meeting of the European
Association for the Study of the Liver (EASL).

The  event is  taking place  in Amsterdam,  the Netherlands, from 19 to 23 April
2017, and Dr. Richard Sturgess, Coordinating Investigator of PCI Biotech's phase
I  study in inoperable bile duct cancer, will present the fimaChem poster on 21
April   2017.  The   poster   is   named   "Phase  I  study  with  Photochemical
Internalisation   (PCI)   -  A  novel  technology  for  treatment  of  perihilar
cholangiocarcinoma"  and includes a  brief technology and  method background and
results from the recent fimaChem phase I study.

The  results include an update on interim average overall survival data of 14.5
months  per end March 2017, with 25% of the patients still being alive. Patients
are  on PCI Biotech's phase I study  in inoperable extrahepatic bile duct cancer
for six months, and thereafter followed for survival only.

The median overall survival (OS) in the studies that established gemcitabine and
cisplatin  as standard treatment in  cholangiocarcinoma (CCA) was 11.7 and 11.2
months respectively (Valle et al. NEJM (2010) 362:1273-81 and Okusaka et al. BJC
(2010)  103:469-74). These results may however not be directly comparable to the
data  in the fimaChem  phase I study,  as these studies  include a wide range of
different  inoperable CCA patients, while the  fimaChem phase I study focuses on
inoperable perihilar CCA patients.

About PCI Biotech
PCI   Biotech  is  a  biopharmaceutical  company  focusing  on  development  and
commercialisation  of novel  therapies for  the treatment  of cancer through its
innovative  photochemical  internalisation  (PCI)  technology  platform.  PCI is
applied  to  three  distinct  anticancer  paradigms:  fimaChem  (enhancement  of
chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction
technology  for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics
delivery).

Photochemical  internalisation induces triggered endosomal  release that is used
to  unlock the  true potential  of a  wide array  of therapeutic modalities. The
company's  lead fimaChem  programme consists  of a clinical  Phase I/II clinical
study  in bile  duct cancer,  an orphan  indication with  a high  unmet need and
without  approved products. fimaVacc applies a  unique mode of action to enhance
the  essential cytotoxic effect  of therapeutic cancer  vaccines, which works in
synergy  with several  other state-of-the-art  vaccination technologies. fimaNAc
utilises  the  endosomal  release  to  provide intracellular delivery of nucleic
acids,  such as mRNA and siRNA therapeutics, thereby addressing one of the major
bottlenecks facing this emerging and promising field.

Contact information:
PCI    Biotech    Holding    ASA,   Ullernchausséen   64, N-0379 Oslo,   Norway.
www.pcibiotech.com
Per Walday, CEO, pw@pcibiotech.com , Mobile: +47 917 93 429

This  information is subject to the  disclosure requirements pursuant to section
5 -12 of the Norwegian Securities Trading Act.



 
    

Les om ansvar og rettigheter.